Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

FHTX Stock Forecast

Foghorn Therapeutics stock forecast is as follows: an average price target of $16.33 (represents a 103.87% upside from FHTX’s last price of $8.01) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

FHTX Price Target

The average price target for Foghorn Therapeutics (FHTX) is $16.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $9.00. This represents a potential 103.87% upside from FHTX's last price of $8.01.

FHTX Analyst Ratings

Buy

According to 5 Wall Street analysts, Foghorn Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FHTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Foghorn Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Vikram Purohit	Morgan Stanley	$9.00	$9.32	-3.43%	12.36%
Aug 19, 2024	Gavin Clark-Gartner	Evercore ISI	$20.00	$6.26	219.49%	149.69%
Jan 05, 2023	-	BMO Capital	$20.00	$6.53	206.28%	149.69%
Nov 21, 2022	-	Morgan Stanley	$14.00	$7.87	77.89%	74.78%
Aug 23, 2022	Vikram Purohit	Morgan Stanley	$15.00	$10.89	37.74%	87.27%

Row per page

Go to

The latest Foghorn Therapeutics stock forecast, released on Sep 24, 2024 by Vikram Purohit from Morgan Stanley, set a price target of $9.00, which represents a -3.43% decrease from the stock price at the time of the forecast ($9.32), and a 12.36% increase from FHTX last price ($8.01).

Foghorn Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	2
Avg Price Target	-	$14.50	$14.50
Last Closing Price	$8.01	$8.01	$8.01
Upside/Downside	-100.00%	81.02%	81.02%

In the current month, the average price target of Foghorn Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Foghorn Therapeutics's last price of $8.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 24, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Sep 03, 2024	Jefferies	-	Buy	Initialise
Aug 19, 2024	Evercore ISI	-	Outperform	Initialise
Jun 29, 2023	Goldman Sachs	Buy	Buy	Hold
Jan 05, 2023	BMO Capital	-	Outperform	Initialise
Nov 21, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Aug 23, 2022	Morgan Stanley	Overweight	Hold	Downgrade
May 23, 2022	Morgan Stanley	Overweight	Overweight	Hold

Row per page

Go to

Foghorn Therapeutics's last stock rating was published by Morgan Stanley on Sep 24, 2024. The company gave FHTX a "Equal-Weight" rating, the same as its previous rate.

Foghorn Therapeutics Financial Forecast

Foghorn Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	$17.48M	$5.60M	$5.31M	$4.18M	$6.63M	$4.49M	$3.92M	$713.00K	$41.00K	$279.00K	$286.00K	$251.00K	$179.00K
Avg Forecast	$11.23M	$5.93M	$5.78M	$5.64M	$7.08M	$6.34M	$6.04M	$6.91M	$4.54M	$4.58M	$6.32M	$5.04M	$8.48M	$9.19M	$9.58M	$9.43M	$709.75K	$30.75K	$279.00K	$190.67K	$500.00K	$626.33K
High Forecast	$15.45M	$8.16M	$7.95M	$5.74M	$13.33M	$6.37M	$6.04M	$9.50M	$6.94M	$6.30M	$8.70M	$6.93M	$11.66M	$9.19M	$9.58M	$9.43M	$709.75K	$30.75K	$279.00K	$190.67K	$500.00K	$626.33K
Low Forecast	$9.68M	$5.11M	$4.98M	$5.53M	$4.89M	$6.30M	$6.04M	$5.96M	$1.49M	$3.95M	$5.45M	$4.34M	$7.31M	$9.19M	$9.58M	$9.43M	$709.75K	$30.75K	$279.00K	$190.67K	$500.00K	$626.33K
# Analysts	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	3.81%	0.89%	1.05%	0.49%	0.72%	0.47%	0.42%	1.00%	1.33%	1.00%	1.50%	0.50%	0.29%

Foghorn Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $4.54M, with a low forecast of $1.49M, and a high forecast of $6.94M. FHTX's average Quarter revenue forecast represents a -74.01% decrease compared to the company's last Quarter revenue of $17.48M (Sep 23).

Foghorn Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	$-17.08M	$-31.17M	$-33.32M	$-37.14M	$-24.93M	$-26.49M	$-26.10M	$70.59M	$-24.72M	$-21.83M	$-21.73M	$1.06M	$236.51K
Avg Forecast	$-6.74M	$-3.56M	$-3.47M	$-3.38M	$-4.25M	$-3.80M	$-3.62M	$-4.15M	$-2.73M	$-2.75M	$-3.79M	$-3.02M	$-5.09M	$-5.51M	$-5.75M	$-5.66M	$-425.85K	$-18.45K	$-167.40K	$-22.07M	$-300.00K	$-375.80K
High Forecast	$-5.81M	$-3.07M	$-2.99M	$-3.32M	$-2.93M	$-3.78M	$-3.62M	$-3.57M	$-893.76K	$-2.37M	$-3.27M	$-2.61M	$-4.39M	$-5.51M	$-5.75M	$-5.66M	$-425.85K	$-18.45K	$-167.40K	$-17.66M	$-300.00K	$-375.80K
Low Forecast	$-9.27M	$-4.89M	$-4.77M	$-3.44M	$-8.00M	$-3.82M	$-3.62M	$-5.70M	$-4.16M	$-3.78M	$-5.22M	$-4.16M	$-7.00M	$-5.51M	$-5.75M	$-5.66M	$-425.85K	$-18.45K	$-167.40K	$-26.49M	$-300.00K	$-375.80K
Surprise %	-	-	-	-	-	-	-	-	-	6.21%	8.22%	11.02%	7.30%	4.52%	4.61%	4.61%	-165.77%	1339.84%	130.42%	0.98%	-3.52%	-0.63%

1 analysts predict FHTX's average Quarter EBITDA for Mar 22 to be $-5.66M, with a high of $-5.66M and a low of $-5.66M. This is -108.01% lower than Foghorn Therapeutics's previous annual EBITDA (Dec 21) of $70.59M.

Foghorn Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	$-14.35M	$-29.49M	$-30.49M	$-34.13M	$-23.28M	$-25.44M	$-26.02M	$170.75M	$-26.08M	$-23.11M	$-22.99M	$-68.80K	-
Avg Forecast	$-20.35M	$-26.29M	$-26.29M	$-26.08M	$-22.33M	$-26.92M	$-39.91M	$-39.65M	$-46.58M	$-43.82M	$-44.45M	$-44.29M	$-37.19M	$-29.53M	$-29.53M	$-27.08M	$-38.27M	$-34.82M	$-31.46M	$-23.35M	$-21.79M	$-157.15M
High Forecast	$-16.70M	$-21.58M	$-21.58M	$-23.85M	$-19.78M	$-22.09M	$-32.76M	$-32.55M	$-37.14M	$-35.97M	$-36.48M	$-36.35M	$-30.52M	$-29.53M	$-29.53M	$-27.08M	$-38.27M	$-34.82M	$-31.46M	$-18.68M	$-21.79M	$-157.15M
Low Forecast	$-30.27M	$-39.12M	$-39.12M	$-27.58M	$-26.79M	$-40.06M	$-59.38M	$-59.00M	$-55.42M	$-65.21M	$-66.14M	$-65.90M	$-55.33M	$-29.53M	$-29.53M	$-27.08M	$-38.27M	$-34.82M	$-31.46M	$-28.02M	$-21.79M	$-157.15M
Surprise %	-	-	-	-	-	-	-	-	-	0.33%	0.66%	0.69%	0.92%	0.79%	0.86%	0.96%	-4.46%	0.75%	0.73%	0.98%	0.00%	-

Foghorn Therapeutics's average Quarter net income forecast for Mar 22 is $-27.08M, with a range of $-27.08M to $-27.08M. FHTX's average Quarter net income forecast represents a -115.86% decrease compared to the company's last Quarter net income of $170.75M (Dec 21).

Foghorn Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	$8.31M	$8.40M	$8.64M	$7.86M	$7.96M	$7.70M	$7.22M	$-15.37M	$5.81M	$4.90M	$4.69M	$4.56M	$2.56M
Avg Forecast	$103.73M	$54.76M	$53.37M	$52.05M	$65.41M	$58.54M	$55.78M	$63.81M	$41.95M	$42.32M	$58.41M	$46.52M	$78.29M	$84.56M	$88.21M	$86.80M	$6.53M	$283.03K	$2.57M	$1.75M	$4.60M	$5.76M
High Forecast	$142.66M	$75.32M	$73.41M	$52.97M	$123.09M	$58.85M	$55.78M	$87.76M	$64.08M	$58.21M	$80.33M	$63.98M	$107.68M	$84.56M	$88.21M	$86.80M	$6.53M	$283.03K	$2.57M	$1.75M	$4.60M	$5.76M
Low Forecast	$89.43M	$47.21M	$46.01M	$51.06M	$45.15M	$58.22M	$55.78M	$55.01M	$13.76M	$36.49M	$50.35M	$40.11M	$67.50M	$84.56M	$88.21M	$86.80M	$6.53M	$283.03K	$2.57M	$1.75M	$4.60M	$5.76M
Surprise %	-	-	-	-	-	-	-	-	-	0.20%	0.14%	0.19%	0.10%	0.09%	0.09%	0.08%	-2.35%	20.52%	1.91%	2.67%	0.99%	0.44%

Foghorn Therapeutics's average Quarter SG&A projection for Dec 23 is $41.95M, based on 4 Wall Street analysts, with a range of $13.76M to $64.08M. The forecast indicates a 404.95% rise compared to FHTX last annual SG&A of $8.31M (Sep 23).

Foghorn Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	$-0.34	$-0.70	$-0.73	$-0.82	$-0.56	$-0.61	$-0.63	$4.62	$-0.71	$-0.63	$-0.62	$-0.00	$-0.51
Avg Forecast	$-0.33	$-0.42	$-0.42	$-0.42	$-0.36	$-0.43	$-0.64	$-0.63	$-0.74	$-0.70	$-0.71	$-0.71	$-0.59	$-0.57	$-0.57	$-0.53	$-0.74	$-0.68	$-0.61	$-0.60	$-0.42	$-3.05
High Forecast	$-0.27	$-0.34	$-0.34	$-0.38	$-0.32	$-0.35	$-0.52	$-0.52	$-0.59	$-0.57	$-0.58	$-0.58	$-0.49	$-0.57	$-0.57	$-0.53	$-0.74	$-0.68	$-0.61	$-0.60	$-0.42	$-3.05
Low Forecast	$-0.48	$-0.62	$-0.62	$-0.44	$-0.43	$-0.64	$-0.95	$-0.94	$-0.89	$-1.04	$-1.06	$-1.05	$-0.88	$-0.57	$-0.57	$-0.53	$-0.74	$-0.68	$-0.61	$-0.60	$-0.42	$-3.05
Surprise %	-	-	-	-	-	-	-	-	-	0.49%	0.99%	1.03%	1.38%	0.98%	1.07%	1.20%	-6.23%	1.05%	1.03%	1.03%	0.01%	0.17%

According to 1 Wall Street analysts, Foghorn Therapeutics's projected average Quarter EPS for Mar 22 is $-0.53, with a low estimate of $-0.53 and a high estimate of $-0.53. This represents a -111.36% decrease compared to FHTX previous annual EPS of $4.62 (Dec 21).

Foghorn Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.22	$15.00	1129.51%	Buy
PMVP	PMV Pharmaceuticals	$1.61	$18.00	1018.01%	Buy
STTK	Shattuck Labs	$1.24	$12.00	867.74%	Hold
PRLD	Prelude Therapeutics	$1.04	$6.25	500.96%	Sell
MOLN	Molecular Partners	$5.33	$29.00	444.09%	Buy
ANEB	Anebulo Pharmaceuticals	$1.59	$6.00	277.36%	Buy
CCCC	C4 Therapeutics	$4.31	$13.50	213.23%	Buy
MLYS	Mineralys Therapeutics	$11.48	$30.00	161.32%	Buy
RZLT	Rezolute	$5.29	$13.50	155.20%	Buy
STOK	Stoke Therapeutics	$12.03	$30.60	154.36%	Buy
CGEM	Cullinan Oncology	$13.86	$31.50	127.27%	Buy
FHTX	Foghorn Therapeutics	$8.01	$16.33	103.87%	Buy
EWTX	Edgewise Therapeutics	$31.44	$45.00	43.13%	Buy
NRIX	Nurix Therapeutics	$22.92	$32.20	40.49%	Buy
KYMR	Kymera Therapeutics	$41.96	$51.50	22.74%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

FHTX Forecast FAQ

Is Foghorn Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Foghorn Therapeutics (FHTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of FHTX's total ratings.

What is FHTX's price target?

Foghorn Therapeutics (FHTX) average price target is $16.33 with a range of $9 to $20, implying a 103.87% from its last price of $8.01. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Foghorn Therapeutics stock go up soon?

According to Wall Street analysts' prediction for FHTX stock, the company can go up by 103.87% (from the last price of $8.01 to the average price target of $16.33), up by 149.69% based on the highest stock price target, and up by 12.36% based on the lowest stock price target.

Can Foghorn Therapeutics stock reach $12?

FHTX's average twelve months analyst stock price target of $16.33 supports the claim that Foghorn Therapeutics can reach $12 in the near future.

What are Foghorn Therapeutics's analysts' financial forecasts?

Foghorn Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.37M (high $35.25M, low $23.19M), average EBITDA is $-15.823M (high $-13.915M, low $-21.147M), average net income is $-129M (high $-107M, low $-185M), average SG&A $243.54M (high $325.48M, low $214.17M), and average EPS is $-2.058 (high $-1.712, low $-2.959). FHTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.58M (high $37.29M, low $25.31M), average EBITDA is $-17.147M (high $-15.185M, low $-22.374M), average net income is $-99.017M (high $-83.709M, low $-136M), average SG&A $263.91M (high $344.36M, low $233.72M), and average EPS is $-1.582 (high $-1.337, low $-2.174).

Did the FHTX's actual financial results beat the analysts' financial forecasts?

Based on Foghorn Therapeutics's last annual report (Dec 2023), the company's revenue was $34.16M, beating the average analysts forecast of $20.49M by 66.71%. Apple's EBITDA was $-108M, beating the average prediction of $-12.293M by 777.81%. The company's net income was $-98.426M, missing the average estimation of $-179M by -45.06%. Apple's SG&A was $32.37M, missing the average forecast of $189.2M by -82.89%. Lastly, the company's EPS was $-0.0023, missing the average prediction of $-2.861 by -99.92%. In terms of the last quarterly report (Sep 2023), Foghorn Therapeutics's revenue was $17.48M, beating the average analysts' forecast of $4.58M by 281.38%. The company's EBITDA was $-17.081M, beating the average prediction of $-2.75M by 521.20%. Foghorn Therapeutics's net income was $-14.345M, missing the average estimation of $-43.822M by -67.27%. The company's SG&A was $8.31M, missing the average forecast of $42.32M by -80.37%. Lastly, the company's EPS was $-0.34, missing the average prediction of $-0.7 by -51.43%